Spontaneous pneumomediastinum, pneumothorax and subcutaneous emphysema in COVID-19 pneumonia: a rare case and literature review

Tarig Sami Elhakim, Haleem S Abdul, Carlos Pelaez Romero, Yoandy Rodriguez-Fuentes

SUMMARY
Spontaneous pneumomediastinum (SPM) and pneumothorax (PNX) unrelated to positive pressure ventilation has been recently reported as an unusual complication in cases of severe COVID-19 pneumonia. The presumed pathophysiological mechanism is diffuse alveolar injury leading to alveolar rupture and air leak. We present a case of COVID-19 pneumonia complicated on day 13 post admission by SPM, PNX and subcutaneous emphysema in a patient with no identifiable risk factors for such complication. The patient received medical treatment for his COVID-19 infection without the use of an invasive or non-invasive ventilator. Moreover, he is a non-smoker with no lung comorbidities and never reported a cough. He was eventually discharged home in stable condition. A comprehensive literature review revealed 15 cases of SPM developing in patients with COVID-19 pneumonia.

BACKGROUND
By the end of 2019, several cases of pneumonia with unknown aetiology were reported in Wuhan, China. Most cases progressed to acute respiratory distress syndrome (ARDS). Later on, a novel coronavirus was identified, which was named SARS-CoV-2 and the disease implicated by the virus as ‘COVID-19’. Despite travel restrictions and quarantine measures, the number of COVID-19 cases continued to rise worldwide, leading to declaration of a COVID-19 pandemic on 11 March 2020. The intrusive nature of COVID-19 has left the physicians to deal with some of its untoward complications.

Here, we present a rare case of SARS-CoV-2 pneumonia complicated by spontaneous pneumomediastinum (SPM), pneumothorax (PNX) and subcutaneous emphysema (SCE) without the use of an invasive or non-invasive ventilator. Despite the potential for a worse outcome, the patient fortunately survived and had a good clinical outcome. After an extensive literature review, we identified 15 cases in the literature that developed SPM with COVID-19 and most had a favourable clinical outcome with close observation and conservative management.

CASE PRESENTATION
A 63-year-old man with a medical history of hypertension and type 2 diabetes mellitus presented to the emergency department with 2 days of worsening non-exertional shortness of breath associated with fever and fatigue. The patient was exposed to positive patients with COVID-19 at work. He then developed upper respiratory tract symptoms and was tested positive 8 days before presentation. He denied cough, chest pain, nausea, vomiting or headaches. He does not consume alcohol, smoke tobacco or use recreational drugs.

On arrival, the physical examination revealed a calm patient with no apparent respiratory distress. His oxygen saturation was 88%–90% on room air, which improved to 96% on a non-rebreather mask at 15 L/min. His respiratory rate was 24 breaths/min, temperature was 37.1°C, pulse 98 bpm and blood pressure 111/61 mm Hg. Examination of the lung revealed bilateral ronchi; otherwise, the rest of his physical examination was benign.

His initial chest X-ray showed bilateral infiltrates and widening of the mediastinum (figure 1). Therefore, a chest CT was obtained, which showed an extensive bilateral peripheral ground-glass infiltrates, but no mediastinal pathology was noted (figure 2). Laboratory studies were remarkable for normal white cell count 8.1×10⁹/L with a neutrophil count of 90% and lymphocyte count of 5%. His sodium was 132 mmol/L. Arterial blood gas on a non-rebreather mask at 15 L/min showed a pH of 7.5, pCO₂ of 27.5, pO₂ of 180.6 and HCO₃ of 21. Reverse transcriptase PCR of COVID-19 was positive. His D-dimer was initially 2276 ng/mL. Ferritin 3110 ng/mL, lactate dehydrogenase (LDH) 804 U/L and C reactive protein 6.8 mg/dL. The patient completed a course of ceftriaxone, dexamethasone sodium phosphate, and then meropenem and remdesivir.

Throughout hospitalisation, the patient was on supplemental oxygen and underwent frequent self-proning. At no point he required the use of any positive pressure oxygen devices. On hospital day 13, he developed hypothermia, hypotension and elevated lactic acid. Physical examination was pertinent for a crepitus sensation in the neck and an audible crunching sound on cardiac auscultation. His pO₂/FiO₂ ratio decreased to 116. Repeat CT scan of the chest showed extensive pneumomediastinum (PM) with mass effect on the anterior cardiac border associated with biapical pneumothoraces with persistent ground-glass opacity (figure 3). Additionally, SCE extending superiorly to the base of the bilateral neck, anteriorly to the right chest...
wall and posteriorly to the bilateral scapula was noted (figure 3). The patient was rushed to the intensive care unit (ICU) and observed in the critical care setting. His haemodynamic status improved after a bolus of isotonic saline, albumin therapy and initiation of a hair hugger. The patient stayed 1 day in the ICU and was resting comfortably in the bed, in no acute distress and all vital signs stable. Therefore, he was downgraded to the intermediate care unit. Cardiothoracic surgery was consulted. Their recommendations were to closely monitor the clinical status of the patient and do serial chest x-rays. The patient was managed supportively. His clinical status continued to be stable with no haemodynamic compromise. His oxygen requirements continued to decrease and the patient was transitioned from a non-rebreather to a nasal cannula at 2 L/min. Repeat CT scan of the chest showed improvement of the PM, SCE and pneumothoraces (figure 4).

OUTCOME AND FOLLOW-UP
During the following 1 month, the patient showed tremendous clinical improvement. He underwent extensive physical rehabilitation and responded well. His oxygen requirements transitioned to room air. His SCE resolved and the follow-up chest radiography showed a complete resolution of the PNX and significant improvement of the PM (figure 4).

DISCUSSION
SARS-CoV-2 is a positive-stranded RNA virus with a crown-like appearance. It shares 89% of the nucleotide sequence found in the bat SARS-like isolate CoVZXC21 and 82% with the human SARS-CoV. Transmission is from human to human with droplet transmission representing the most common form, although aerosol transmission has also been suggested. Contact with contaminated objects is another source of transmission. The incubation period ranges from 2 to 14 days and symptoms can include fever, malaise, dry cough, dyspnoea, sore throat, nasal congestion, headache, muscle pain, loss of taste and/or smell, diarrhoea and vomiting. Most cases are mild, while others can progress to pneumonia, sepsis, ARDS and/or multiorgan failure.

The virus enters the cells through the Angiotensin-Converting Enzyme 2 (ACE2) receptor, which is extensively expressed in the alveolar cells of the lungs. An excessive host immune response can be triggered, leading to extensive tissue damage. Interleukin (IL)-6 is considered a main trigger of such an immune response. Another factor is the release of IL-1B, which causes extensive inflammation and eventual fibrosis of the lung. The most frequent radiographical finding is ground-glass opacities occurring in the intermediate/late phase and reticular alterations occurring in the early phase. Distribution is usually bilateral, peripheral and with middle/lower predominance. Consolidation gradually occurs over time.

An uncommon presentation of COVID-19 is the occurrence of SPM, PNX and SCE. PM, also known as mediastinal emphysema, is the presence of air tracking along the mediastinum. It can be spontaneous (SPM) or traumatic. Mechanical ventilation causing barotrauma, blunt or penetrating trauma to the chest or iatrogenic injury (eg, thoracic surgery) are examples of traumatic SPM. SPM can be primary, in which no underlying lung disease is present, or secondary, in which an underlying lung or airway disease that predisposes to air leak is present. Examples of secondary SPM include asthma or cystic fibrosis. PM can also be classified into benign or malignant PM, which can be fatal. Benign forms can turn malignant when, for example, the pressure in the mediastinum rises rapidly and there is no escape route to the neck or retroperitoneum, or air escapes into the bilateral pleural cavities causing bilateral PNX, which can turn into a tension PNX, especially with the presence of cough. Malignant PM can result in mechanical obstruction, which will interfere with the heart and the blood vessels, causing a decrease in circulation.

PM is considered a rare occurrence, with the incidence being 1/25 000 in ages between 5 and 34 years. The majority are men, representing 76% of the cases, and it is more frequent in children (1/800 to 1/15 500). One explanation is that children have loose mediastinal tissue compared with adults who have fibrosed sheath, making air migration difficult.

The pathophysiology of SPM is based on the Macklin phenomenon, which describes the occurrence of a large pressure gradient between the marginal alveoli and the lung interstitium, resulting in air leak to the surrounding bronchovascular sheath.
marginal alveoli have their bases in the bronchi, bronchioles, blood vessels and pleura, separated by a connective tissue sheath or the interstitium. This type of alveoli can let air escape into the connective tissue sheath, which can result in pulmonary interstitial emphysema, leading to PM. The other partitional alveoli have pores between the adjacent alveoli, causing air to pass to the adjoining ones, preventing such occurrence.

One mechanism is an increase in intrathoracic pressure, resulting in an increase in intra-alveolar pressure and overinflation of the alveoli without corresponding expansion of the vascular lumen. This will result in a pressure gradient that can rupture the marginal alveoli, leading to air leaking to the interstitium which can track along the perivascular and peribronchial sheath to the hilum of the lung and then to the low pressure mediastinum. Examples of such mechanisms include cough, vomiting, sneezing, defecation or asthma exacerbation.

The second mechanism is caused by a reduction in the calibre of the pulmonary vessels, without a corresponding diminution of the alveolar pressure. This will increase the pressure gradient causing air leak to the sheath. Examples include forced expiration against obstruction which will dam the blood back to the venous side decreasing the vascular calibre, but the alveolar end-expiratory pressure is higher than normal. This can increase the pressure gradient, resulting in air leak and PM.

Both mechanisms can occur simultaneously in which the alveoli is overdistended while the blood calibre is decreased. This will increase the pressure gradient significantly, inducing air leak more easily. An example of such occurrence is when men escaping from a submarine ascend to the surface and hold their breath. This will lessen the pressure on the chest and permit the expansion of the alveoli without equalising its pressure with that on the chest. Holding the breath will stagnate the venous blood therefore, lessening the pulmonary vessel calibre. This will increase the alveolar gradient significantly, inducing PM. Scuba diving is another example that can cause PM. As divers descend, the lung volume decreases and air in the lungs become compressed, resulting in pulmonary oedema and haemorrhage. When divers ascend, the transalveolar pressure increases, resulting in overexpansion of the alveoli and alveolar rupture. Air will then leak along the connective tissue sheath to the lung hilum, causing PM. Risk of occurrence is increased when divers hold their breath as they ascend or in those with obstructive lung disease.
| Date of publishing | Author/country | Cases (n) | Age | Gender | Comorbidities and smoking | Received non-invasive ventilator | Diagnosis | Treatment | Outcome |
|--------------------|----------------|-----------|-----|--------|---------------------------|--------------------------------|-----------|-----------|---------|
| March 2020         | Wang et al,50 China | 1 | 36  | Female | None                       | Yes                            | Spontaneous pneumomediastinum | Conservative | Expired |
| April 2020         | Wang et al,51 China | 1 | 62  | Male   | None                       | Yes                            | Spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema | Conservative | Recovered |
| March 2020         | Zhou et al,52 China | 1 | 38  | Male   | None                       | No                             | Spontaneous pneumomediastinum and subcutaneous emphysema | Conservative | Recovered |
| May 2020           | Mohan et al,53 USA | 1 | 49  | Male   | Hypertension and type 2 diabetes | No                             | Spontaneous pneumomediastinum with subcutaneous emphysema | Conservative | Recovered |
| June 2020          | Romano et al,54 Italy | 2 | 30  | Male   | Unknown                    | Unknown                        | Spontaneous pneumomediastinum with subcutaneous emphysema | Conservative | Recovered |
| May 2020           | Sun et al,55 China | 1 | 38  | Male   | None                       | Yes                            | Mediastinal emphysema, giant bulla and pneumothorax | Conservative | Recovered |
| June 2020          | Murillo Brito et al,56 Spain | 1 | 58  | Male   | None                       | No                             | Spontaneous pneumomediastinum, pneumopericardium and subcutaneous emphysema | Conservative | Recovered |
| June 2020          | Brogna et al,57 Italy | 2 | 78  | Female | Diabetes mellitus and hypertension | Yes                            | Spontaneous pneumomediastinum | Conservative | Recovered |
| June 2020          | López Vega et al,58 Spain | 3 | 84  | Female | Prosthetic valve replacement, renal failure, heart failure, hypertension and hypercholesterolemia | No                             | Right partial hydropneumothorax, left full hydropneumothorax and pneumomediastinum | Conservative | Expired |
|                    |                | 67  | Male | None   |                            | No                             | Bilateral apical pneumothorax and pneumomediastinum | Chest tube for the pneumothorax | Expired |
|                    |                | 73  | Male | Basal cell epithelioma, obstructive sleep apnea, obesity and depression | Yes                            | Pneumomediastinum | Conservative | Expired |
| May 2020           | Kolani et al,59 Morocco | 1 | 23  | Female | None                       | No                             | Pneumomediastinum | Conservative | Recovered |
| May 2020           | Lei et al,60 China | 1 | 64  | Male   | None                       | Unknown                        | Spontaneous pneumomediastinum | Conservative | Recovered |
Other predisposing factors of SPM include tobacco or marijuana smoking, illicit drug use (such as heroin, cocaine or nitrous oxide),23–25 interstitial lung disease, lung infections and vigorous Valsalva manoeuvres.26

SPM was first described in 1819 by Laennec26 and was further characterised in 1939 by Hamman27 who reported a case series of patients presenting with SPM and SCE. Hamman then described the mediastinal crunching sound heard during auscultation over the cardiac apex and the left sternal border that is synchronous with the heartbeat, which is named the Hamman’s sign.28 Additionally, Muller noted the bubbling crepitations that occur with heart beat and the disappearance of the cardiac dullness.29 Common presenting symptoms include chest pain that occur with heart beat and the disappearance of the cardiac dullness.29

Viral respiratory infections can rarely cause SPM, PNX and SCE. It has been reported with cytomegalovirus pneumonitis,42 pneumocystis pneumonia,36 and critical pertussis.40 In HIV infection,9 pneumocephaloe12,36 and influenza infections.37–39 The pathophysiological reasons discussed in those cases follow the Macklin phenomenon. In case of influenza, the cough leads to increased alveolar pressure and eventual rupture. In case of measles, the airway obstruction from secretions or enlarged lymph nodes result in hyperinflation of the alveoli, increasing the pressure gradient.37

A retrospective analysis of SARS-CoV database identified 13 patients who developed SPM with or without PNX and SCE at a mean of 19.6±4.5 days from symptom onset.49 No patient had isolated PNX and all were unrelated to the use of invasive or non-invasive positive pressure ventilation. Four patients died, two of them after intubation. Others who survived took a mean of 19.6±4.6 days from symptom onset.49 No patient had isolated PNX and all were unrelated to the use of invasive or non-invasive positive pressure ventilation.49 Four patients died, two of them after intubation. Others who survived took a mean of 28 days to resolve completely. Analysis showed that high peak serum LDH, which might signify cellular damage, was associated with the development of SPM. The authors postulate that severe diffuse alveolar damage is the cause of the alveolar rupture that results in interstitial emphysema and air tracking along the bronchoalveolar sheath to the mediastinum. Viral load was not related to its development, suggesting that other mechanisms behind viral-induced cytokysis might be important in the pathogenesis of alveolar damage (eg, immunological injury).

Our review of literature has identified 15 cases of SPM developing in patients with COVID-19 (table 1).50–60 These cases illustrate the severity of COVID-19 and its spontaneous complications. Six of these cases were associated with PNX. Another six cases were associated with SCE and one with pneumopericardium. Such complication was identified in some patients during initial presentation to the hospital, while others developed it during the course of the hospitalisation. Our patient developed SPM, PNX and SCE on day 13 of the hospitalisation. Similar to our case, seven of these cases did not use any sort of invasive or non-invasive positive pressure ventilator before the development of the SPM. This suggests that other processes related to COVID-19 might be the mechanism of air leak that progress to SPM, PNX and/or SCE. This suggestion is even supported by the absence of smoking history in all of these patients and the absence of significant comorbidities that can predispose to air leak. Our patient has a history of hypertension and diabetes with no history of lung disease or smoking. Studies suggest that a dysregulation of the immune response seen with SARS-CoV-2, SARS-CoV or MERS-CoV could be a cause of the significant lung injury causing an ARDS pattern.61–62 Fox et al63 published a case series of COVID-19 autopsies and found that the dominant process in all cases was the diffuse alveolar damage with a monocellular response around thrombosed small vessels. They suggest that the maladaptive immune response plays a significant role in severe COVID-19. This may suggest that the mechanism of air leak seen with COVID-19 could be related to the significant alveolar damage, which make the alveolar wall more prone to rupture. The rupture could be exacerbated by cough or anything that increases the alveolar pressure. In our hospital, we identified eight patients who developed air leak after the application of an invasive or non-invasive positive pressure ventilator. This is the only patient who did not receive such positive pressure oxygenation and did not complain of a cough. This suggests that patients with COVID-19 are at high risk of developing air leaks that can precipitate with anything that increases the alveolar pressure. Therefore, care should be taken to mitigate reasons of increased alveolar pressure such as cough and positive pressure ventilators based on the Macklin phenomenon.

Fortunately, our patient recovered and his follow-up CT scan showed significant improvement. He had no complications during the follow-up period. Additionally, most of the cases identified during the literature review showed spontaneous resolition with conservative management. Eleven patients recovered

Learning points

► In patients with confirmed or suspected COVID-19, the development of acute or worsening dyspnea with rapid deterioration of clinical status is suspicious for the presence of spontaneous pneumomediastinum (SPM) or pneumothorax (PNX). Evaluate for the presence of subcutaneous emphysema, auscultate for the Hamman sign and perform a CT scan of the chest.

► SPM and PNX should be suspected even if the patient has not received an invasive or non-invasive positive pressure ventilator, did not complain of a cough or has no significant comorbidities, including a history of lung disease or smoking.

► High serum lactate dehydrogenase might signify an elevated risk of SPM in patients with COVID-19.

► The presumed pathophysiological mechanism is diffuse alveolar damage and alveolar rupture, leading to interstitial emphysema and air tracking along the bronchoalveolar sheath to the mediastinum.

► Most of the cases have a spontaneous resolution with conservative management, which consists of close monitoring, bed rest, analgesia and oxygen therapy. Additionally, identify and manage any precipitating factor.
and had a favourable clinical course, whereas four patients expired, resulting in a mortality rate of 26%, based on available literature. Therefore, SPM is mostly a self-limiting benign condition and treatment is mainly conservative with bed rest, analgesia and oxygen therapy.30 31 64 However, in all cases, close monitoring is pertinent and any precipitating factors should be identified and managed to avoid potential serious complications. High serum LDH might signify an elevated risk of SPM and PNX should be considered in the differential diagnosis of worsening disease in patients with COVID-19. Further research with a larger number of cases is needed in this area.

Twitter Tarig Sami Elhakim @TarigElhakim

Acknowledgements We would like to thank our Program Director’s Dr Jose Gascon and Dr Robert Hernandez, for their tremendous support and dedication toward the internal Medicine and Transitional Year Residency program at Kendall Regional Medical Center. Additionally we would like to thank our Associate program director Dr Vanina Molinaris and our faculty members Dr Jose Barros, Dr Jose Gonzalez-Pantaleon, Dr Roberto Ruiz, Dr Manuel Lee, Dr Walter Ramirez, among others. All has provided us with an environment full of support, education and joy. Moreover we would like to thank all the frontline workers fighting against the COVID-19 pandemic and our endless convalescence to those who suffered or suffering from COVID-19.

Contributors TS is responsible for the overall content as a guarantor. He accepts full responsibility for the work and controlled the decision to publish. He managed the case with the rest of the authors. He performed the literature search and wrote the initial draft of the article and case description. HSA has provided the appropriate guidance to write and publish the article. He initiated and revised the article. Additionally, he participated in the direct management of the patient. CP has participated in the writing of the article, the lessons to learn section and the revision of the article. Additionally, he participated in the direct management of the patient. YR-F brought the idea of the article to the team and contributed in the revision and editing of the article. He participated in the direct management of the patient.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer-reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iD Tarig Sami Elhakim http://orcid.org/0000-0002-5038-9232

REFERENCES

1  Li H, Stratton CN, Tang Y-W. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med ViroL 2020;92:401–2.
2  Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
3  Hui DS, I Azhar E, Madani TA, et al. The continuing 2019 novel coronavirus (2019-nCoV) outbreak in Wuhan, China. Int J Infect Dis 2020;91:264–6.
4  WHO pneumonia of unknown cause – China. Available: https://www.who.int/csr/don/ 03-january-2020-pneumonia-of-unknown-cause-china/en/
5  Almeida JD, Berry DM, Cunningham CH, et al. Virology: coronaviruses. Nature 1968;220:650.
6  Chan JF-W, Kok K-H, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020;9:221–3.
7  Castella M, Rajnik M, Cuomo A. Features, Evaluation and Treatment Coronavirus (COVID-19). In: StatPearls [Internet], Treasure Island, FL: StatPearls Publishing, 2020. https://www.ncbi.nlm.nih.gov/books/NBK554776/
8  van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020;382:1564–7.
9  Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–9.
10  Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.
11  Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020;323:1239–1242.
12  Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270–3.
13  Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;46:586–90.
14  Conti P, Ronconi G, Canaﬁ A, et al. Induction of pro-inﬂammatory cytokines (IL-1 and IL-6) and lung inﬂammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inﬂammatory strategies. J Biol Regul Homeost Agents 2020;34:1.
15  Vancheri SG, Savietto G, Ballari F, et al. Radiographic ﬁndings in 240 patients with COVID-19 pneumonia: time-dependence after the onset of symptoms. Eur Radiol 2020;1–9.
16  Mascon R. Chapter 72: Pneumomediastinum and mediastinitis. In: Murray and Nadel’s textbook of respiratory medicine. 4th edn. Elsevier Health Sciences, 2005.
17  Macklin MT, Macklin CC. Malignant intestinal stenosis of the lungs and mediastinum as an important occult complication in many respiratory diseases and other conditions: interpretation of the clinical literature in the light of laboratory experiment. Medicine 1944;23:281–358.
18  Jougion JB, Ballester M, Delcombe F, et al. Assessment of spontaneous pneumomediastinum: experience with 12 patients. Ann Thorac Surg 2003;75:1711–4.
19  Agut A, Talavera J, Buendia A, et al. Imaging diagnosis-spontaneous pneumomediastinum secondary to primary pulmonary pathology in a dalmatian dog. Vet Radiol Ultrasonogr 2015;56:654–7.
20  Kourtis VK, Papagiannopoulos K, Lazaridis G, et al. Pneumomediastinum. J Thorac Dis 2015;7:544–9.
21  Hardy KR. Diving-related emergencies. Emerg Med Clin North Am 1997;15:223–40.
22  Colebatch HJ, Smith MM, Ng CK. Increased elastic recoil as a determinant of pulmonary barotrauma in divers. Respir Physiol 1976;26:55–64.
23  Frenkel MA, Lyons LL. Spontaneous pneumomediastinum. An unusual cause of a sore throat. Postgrad Med J 1991;69:257–9.
24  Mattok KL. Pneumomediastinum in heroin and marijuana users. JACEP 1976;5:26–8.
25  LiPuma JP, Wellman J, Stern HP. Nitrous oxide abuse: a new cause of pneumomediastinum. Radiology 1982;145:602.
26  Sahni S, Verma S, Grullon J, et al. Spontaneous pneumomediastinum: time for consensus. N Am J Med Sci 2013;5:460–4.
27  Hamman L. Spontaneous mediastinal emphysema. Bull Johns Hopkins Hosp 1939;64:1–21.
28  Kobashi Y, Okimoto N, Matsuhashi T, et al. Comparative study of mediastinal emphysema as determined by etiology. Intern Med 2002;41:277–82.
29  Munroe DS, Webb GA, LinzRM. Spontaneous mediastinal emphysema. Can Med Assoc J 1943;84:256–61.
30  Mada I, Moya J, Ramos R, et al. Spontaneous pneumomediastinum: 41 cases. Eur J Cardiothorac Surg 2007;31:1110–4.
31  Caceres M, Ali S2, Braud R, et al. Spontaneous pneumomediastinum: a comparative study and review of the literature. Ann Thorac Surg 2008;86:962–6.
32  Allen CJ, Teisch LF, Stahl KD. Spontaneous pneumomediastinum, pneumopericardium and epidural pneumotaxis: insights on clinical management. Acute Cardare Care 2015;17:20–3.
33  Varo N, Bugin S, Snijders D, et al. Pneumomediastinum and pneumopericardium in an 11-year-old rugby player: a case report. J Athl Train 2013;48:277–81.
34  Belotti EA, Rizzi M, Rodoni-Casspi P, et al. Air within the spinal canal in spontaneous pneumomediastinum. Chest 2010;137:1197–200.
35  Iyer VN, Josh AJ, Ryan JL. Spontaneous pneumomediastinum: analysis of 62 consecutive adult patients. Mayo Clin Proc 2009;84:417–21.
36  Oude K, Caliskan U, Emilik D, et al. Pneumomediastinum and pneumopericardium due to intracavitary aspergillosis: an unusual complication of fungal pneumonia. Pediatr Radiol 2002;32:143–5.
37  Vázquez JL, Vázquez I, González ML, et al. Pneumomediastinum and pneumothorax as presenting signs in severe Mycoplasma pneumoniae pneumonia. Pediatr Radiol 2007;37:1286–8.
38  Yates SP, Morcos SK. Delayed tension pneumothorax complicating staphylococcal pneumonia. Postgrad Med J 1998;74:796–8.
39  Kofedris DP, Bouros DE, Vamvakas LN, et al. Pneumothorax complicating fatal bronchiolitis obliterans organizing pneumonia. Respiration 1999;66:266–8.
40  Monaco F, Barone M, Marfedi VG, et al. Pneumomediastinum and pertussis. Clin Resp J 2016;10:772–6.
Pneumothorax in HIV-infected patients: role of Pneumocystis carinii pneumonia and pulmonary tuberculosis. *Eur Respir J* 1997;10:1332–5.

Dillif JF, Williams MP. Radiological appearances of cytomegalovirus infections. *Clin Rad* 1989;40:463–7.

Muco E, Kushi A, Haniti A, et al. Pneumomediastinum and subcutaneous emphysema following measles in a patient with diabetes and under Corticotherapy. *J Eme Med Int Care* 2018;3:129.

Singh BP, Shetty GS, Vijayan PA, et al. Management of pneumomediastinum associated with H1N1 pneumonia: a case report. *J Crit Care Med* 2019;5:28–33.

Park SY, Kim M-G, Kim EJ, et al. Spontaneous pneumomediastinum, pneumothorax, and subcutaneous emphysema complicating H1N1 virus infection. *Korean J Med* 2011;80.

Yamada K, Shimoto H, Hamamoto M, et al. Pneumonia induced by swine-origin influenza A (H1N1) infection: chest computed tomography findings in children. *Jpn J Radiol* 2011;29:712–7.

Udapa S, Hameed T, Kovezi T. Pneumomediastinum and subcutaneous emphysema associated with pandemic (H1N1) influenza in three children. *CMAJ* 2011;183:220–2.

Luis BAL, Navarro AO, Palacios GMR. Pneumomediastinum and subcutaneous emphysema associated with influenza A H1N1 virus. *Lancet Infect Dis* 2017;17:671.

Chu CM, Leung YY, Hui JYH, et al. Spontaneous pneumomediastinum in patients with severe acute respiratory syndrome. *Eur Respir J* 2004;23:802–4.

Wang J, Su X, Zhang T, et al. Spontaneous pneumomediastinum: a probable unusual complication of coronavirus disease 2019 (COVID-19) pneumonia. *Korean J Radiol* 2020;21:627–8.

Wang W, Gao R, Zheng Y, et al. COVID-19 with spontaneous pneumomediastinum, pneumomediastinum and subcutaneous emphysema. *J Travel Med* 2020;27:taaa062.

Zhou C, Gao C, Xie Y, et al. COVID-19 with spontaneous pneumomediastinum. *Lancet Infect Dis* 2020;20:510.

Moham V, Tausen RA. Spontaneous pneumomediastinum in COVID-19. *BMJ Case Rep* 2020;13:e236519.